Microinfusion of the non-competitive N-methyl-D-aspartate receptor antagonist MK-801 (dizocilpine) into the dorsal hippocampus of Wistar rats does not affect latent inhibition and prepulse inhibition, but increases startle reaction and locomotor activity

Neuroscience

Volumn 101, Issue 3, 2000, Pages 589-599

  Zhang, W N ^a   Bast, T ^a   Feldon, J ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Animal model; NMDA receptor; Schizophrenia; Sensory and attentional gating

Indexed keywords

DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; EMOTION; HIPPOCAMPUS; LATENT INHIBITION; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STARTLE REFLEX;

ANIMALS; ATTENTION; CONDITIONING (PSYCHOLOGY); DIZOCILPINE MALEATE; EMOTIONS; HIPPOCAMPUS; MALE; MOTOR ACTIVITY; NEURAL INHIBITION; NEURONS; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SENSATION; STARTLE REACTION;

EID: 0034669064     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00418-8     Document Type: Article

References (85)

1. Effects of CS preexposures on avoidance learning in rats with hippocampal lesions
2. Effects of the NMDA receptor antagonist ketamine on memory: conditioned aversion, latent inhibition, and habitutation of neophobia
3. Temporally graded retrograde amnesia of contextual fear after hippocampal damage in rats: within-subjects examination
4. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist, dizocilpine
5. Alpha-1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats
6. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response
7. Double dissociation of function within the hippocampus: a comparison of dorsal, ventral, and complete hippocampal cytotoxic lesions
8. A topographic event-related potential follow-up study on 'prepulse inhibition' in first and second episode patients with schizophrenia
9. Sensorimotor gating and schizophrenia: human and animal model studies
10. Gating and habituation of the startle reflex in schizophrenic patients
11. Carbachol infusion into the dentate gyrus disrupts sensorimotor gating of the startle reflex in rats
12. Hippocampal modulation of acoustic startle and prepulse inhibition in the rat
13. Aspiration lesions of rats' ventral hippocampus disinhibit responding in conditioned suppression or extinction, but spare latent inhibition and the partial reinforcement extinction effect
14. Entorhinal but not hippocampal or subicular lesions disrupt latent inhibition in rats
15. MK-801 increases locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens
16. An integrated view of the pathophysiological models of schizophrenia
17. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias
18. The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating
19. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia
20. Amygdaloid N-methyl-D-aspartate and γ-aminobutyric acid(A) receptors regulate sensorimotor gating in a dopamine-dependent way in rats
21. Tetrodotoxin inactivation of the gustatory cortex disrupts the effect of the N-methyl-D-aspartate antagonist ketamine on latent inhibition of conditioned taste aversion in rats
22. Dorsal hippocampal lesions impair blocking but not latent inhibition of taste aversion learning in rats
23. Startle response models of sensorimotor gating and habituation deficits in schizophrenia
24. Dissociable effects of selective lesions to hippocampal subsystems on exploratory behaviour, contextual learning and spatial learning
25. Integrating schizophrenia
26. The neuropsychology of schizophrenia
27. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia
28. Latent inhibition: the nucleus accumbens connection revisited
29. NMDA-dependent modulation of CA1 local circuit inhibition
30. N-Methyl-D-aspartate receptor antagonists reduce synaptic excitation in the hippocampus
31. Hippocampal lesions disrupt decrements but not increments in conditioned stimulus processing
32. The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK801
33. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input
34. Muscimol inactivation of the dorsal hippocampus impairs contextual retrieval of fear memory
35. Selective hippocampal lesions abolish the contextual specificity of latent inhibition and conditioning
36. Recent advances in the phencyclidine model of schizophrenia
37. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats
38. Hippocampal lesions attenuate latent inhibition and the decline of the orienting response in rats
39. Hippocampal lesions attenuate latent inhibition of a CS and of a neutral stimulus
40. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle
41. Rat strain differences in the ability to disrupt sensorimotor gating are limited to the dopaminergic system, specific to prepulse inhibition, and unrelated to changes in startle amplitude or nucleus accumbens dopamine receptor sensitivity
42. Induction of Fos-protein in the forebrain and disruption of sensorimotor gating following N-methyl-D-aspartate infusion into the ventral hippocampus of the rat
43. The neurobiology of startle
44. Spatial and temporal patterning distinguishes the locomotor activating effects of dizocilpine and phencyclidine in rats
45. The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems
46. Latent inhibition
47. Latent inhibition in humans: data, theory and implications for schizophrenia
48. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rats
49. Neurotoxic lesions of the dorsal hippocampus and Pavlovian fear conditioning in rats
50. Prazosin inhibits MK-801 induced hyperlocomotion and dopamine release in the nucleus accumbens
51. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens
52. Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomotor activity
53. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization
54. A relationship between the inhibition of the acoustic startle response and the protection of prepulse processing
55. Information prosessing and attentional functioning in the developmental course of schizophrenic disorders
56. NMDA receptor hypofunction model of schizophrenia
57. Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats
58. Light and electron microscope distribution of the NMDA receptor subunit NMDAR1 in the rat nervous system using a selective anti-peptide antibody
59. The effects of hippocampal and fimbria-fornix lesions on prepulse inhibition
60. Enhancement of latent inhibition in rats with electrolytic lesions of the hippocampus
61. Ibotenate lesions of the hippocampus enhance latent inhibition in conditioned taste aversion and increase resistance to extinction in conditioned taste preference
62. Dissociating context and space within the hippocampus: effects of complete, dorsal and ventral excitotoxic lesions on conditioned freezing and spatial learning
63. Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants
64. A functional neuroanatomy of schizophrenia
65. 3H]3-OH-PCP (1-(1-(3-hydroxyphenyl)cyclohexyl)piperidine) binding sites in rat brain
66. Animal models of sensorimotor gating: what we know, what we think we know, and what we hope to know soon
67. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
68. The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications
69. Hippocampal lesions enhance startle gating-disruptive effects of apomorphine in rats: a parametric assessment
70. The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm
71. Differences between three rat strains in sensitivity to prepulse inhibition of an acoustic startle response: influence of apomorphine and phencyclidine pretreatment
72. Examination of drug-induced disruption of prepulse inhibition as models to screen antipsychotic drugs
73. The ventral subiculum modulation of prepulse inhibition is not mediated via dopamine D2 or nucleus accumbens non-NMDA glutamate receptor activity
74. Neural substrates of latent inhibition: the switching model
75. Phencyclidine does not disrupt latent inhibition in rats: implication for animal models of schizophrenia
76. The switching model of latent inhibition: an update of neural substrates
77. Hippocampal signal transmission to the pedunculopontine nucleus and its regulation by dopamine D2 receptors in the nucleus accumbens: an electrophysiological and behavioral study
78. Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region, but this lesion effect can be prevented by systemic haloperidol pretreatment
79. NMDA processes mediate anterograde amnesia of contextual fear conditioning induced by hippocampal damage: immunization against amnesia by context preexposure
80. Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics